Latest News and Press Releases
Want to stay updated on the latest news?
-
BUFFALO, N.Y., June 26, 2019 (GLOBE NEWSWIRE) -- OmniSeq, Inc. named Margot P. Schoenborn to succeed Mark Gardner as the chief executive officer of the molecular diagnostics and precision medicine...
-
LONDON and NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- Smart CommunicationsTM, the leading cloud-based platform for enterprise customer communications, today announced the results of its 2019...
-
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you...
-
On 26 June 2019 AKVA group ASA ("AKVA group" or the "Company") purchased 8 897 of its own shares under the buyback program announced by the Company on 2 April 2019. The shares were purchased at an...
-
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you...
-
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss...
-
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss...
-
ARLINGTON, Va., June 26, 2019 (GLOBE NEWSWIRE) -- North American companies making M&A deals, on average, lost shareholder value during the second quarter of 2019, underperforming the MCSI North...
-
ALAMEDA, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided a mid-year...
-
BOSTON, June 26, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced completion of enrollment of the third cohort of a phase 1 clinical trial...